Ascendis Pharma A (ASND) Other Working Capital Changes (2014 - 2026)
Ascendis Pharma A (ASND) posted Other Working Capital Changes of $7.6 million for Q1 2026, down 77.57% sequentially from $34.1 million in Q4 2025, and up 2697.05% YoY from $273490.0 in Q1 2025.
Analysis
Ascendis Pharma A (ASND) Other Working Capital Changes (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Other Working Capital Changes for 8 years, with the latest figure at $7.6 million in Q1 2026.
- Quarterly Other Working Capital Changes rose 2697.05% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.5 million (up 60.73% YoY) and the FY2025 annual result came in at $90.3 million, up 36.38% from the prior year.
- Other Working Capital Changes retreated to $7.6 million in Q1 2026 per ASND's latest filing, from $34.1 million in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $7.1 million in Q3 2023 and troughed at -$10.9 million in Q1 2023.
- A 5-year average of -$1.1 million and a median of -$2.8 million in 2023 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2024 and 2025: Other Working Capital Changes jumped 3826.88% in 2024, then plunged 691.06% in 2025.
- Over 5 years, Other Working Capital Changes stood at $1.2 million in 2022, then jumped by 1059.34% to $14.1 million in 2023, then tumbled by 160.59% to -$8.5 million in 2024, then soared by 499.57% to $34.1 million in 2025, then plunged by 77.57% to $7.6 million in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered $7.6 million, $34.1 million, and -$20.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.39 Mn |
| Jun 30, 2026 | -5.39 Mn |
| Mar 31, 2026 | -5.68 Mn |
| Mar 31, 2026 | -5.68 Mn |
| Dec 31, 2025 | -5.03 Mn |
| Dec 31, 2025 | -5.03 Mn |
| Sep 30, 2025 | 5.93 Mn |
| Sep 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | -1.45 Mn |
| Jun 30, 2025 | -1.45 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Dec 31, 2024 | 5.60 Mn |
| Dec 31, 2024 | 5.60 Mn |
| Sep 30, 2024 | 4.67 Mn |
| Sep 30, 2024 | 4.67 Mn |
| Jun 30, 2024 | 6.21 Mn |
| Jun 30, 2024 | 6.21 Mn |
| Mar 31, 2024 | -4.24 Mn |
| Mar 31, 2024 | -4.24 Mn |